Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lot-to-Lot Consistency of Hexavalent DTaP-IPV-Hep B-PRP-T Vaccine in Infants
NCT01177722Phase 3Completed
- Sponsor
- Sanofi
- Start
- Aug 2010
- Primary completion
- Oct 2011
- Modality
- Recombinant Proteins and Enzymes, Split/Subunit Vaccines
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of DTaP-IPV-Hep B-PRP-T vaccine in diphtheria, Tetanus, pertussis and 3 more (4 arms), sponsored by Sanofi. Primary endpoints: Geometric Mean Titers of Anti-Hepatitis B Antibodies and Seroprotection or Vaccine Response Rates. Started Aug 2010; status: completed.
02
Drugs
DTaP-IPV-Hep B-PRP-T vaccine
03
Conditions
diphtheriaTetanuspertussishepatitis B (HBV)poliomyelitis
Beyond the preview
Go deeper on NCT01177722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01177722.